Asep Medical Confirms the Use of AI – Enables Improved Treatments for Common Biofilm Infections and Rapid Sepsis Diagnostics
VANCOUVER, BC, March 13, 2024 /PRNewswire/ – In a recent presentation to the US Biophysical Society in Philadelphia1, Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) CEO Dr. Bob Hancock announced how the ground-breaking use of artificial intelligence (AI) has allowed the development of new and improved treatments for biofilm infections.
Related news for (SEPSF)
- Asep Medical Featured in National Documentary
- Asep Medical Holdings Inc. to Hold Significant Investor Information Webinar this Friday, March 22, 2024, at 4 pm EST
- Asep Medical’s Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis
- ASEP INC. ANNOUNCES CLOSING OF DEBT SETTLEMENT